Patents Assigned to Velicept Therapeutics, Inc.
  • Solabegron zwitterion and uses thereof
    Patent number: 10844004
    Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: November 24, 2020
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Raymond E. Stevens, Dalian Zhao, Bingidimi Itute Mobele
  • Compositions and methods of using modified release solabegron for lower urinary tract symptoms
    Patent number: 10751311
    Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: August 25, 2020
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Eliot Ohlstein, Raymond E. Stevens, Jr., H. Jeffrey Wilkins
  • PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER
    Publication number: 20200246292
    Abstract: The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of micturitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
    Type: Application
    Filed: April 3, 2020
    Publication date: August 6, 2020
    Applicant: Velicept Therapeutics, Inc.
    Inventors: Stephen CALTABIANO, Eliot OHLSTEIN, Stewart MCCALLUM
  • PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER
    Publication number: 20190365683
    Abstract: The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of micturitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
    Type: Application
    Filed: May 31, 2019
    Publication date: December 5, 2019
    Applicant: Velicept Therapeutics, Inc.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum
  • Pharmaceutical compositions and the treatment of overactive bladder
    Patent number: 10350182
    Abstract: The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of micturitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: July 16, 2019
    Assignee: VELICEPT THERAPEUTICS, INC.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum
  • Solabegron zwitterion and uses thereof
    Patent number: 10221126
    Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: March 5, 2019
    Assignee: VELICEPT THERAPEUTICS, INC.
    Inventors: Raymond E. Stevens, Dalian Zhao, Bingidimi Itute Mobele
  • Solabegron zwitterion and uses thereof
    Patent number: 10065922
    Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: September 4, 2018
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Raymond E. Stevens, Dalian Zhao, Bingidimi Itute Mobele
  • Compositions and methods of using modified release solabegron for lower urinary tract symptoms
    Patent number: 9956194
    Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: May 1, 2018
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Eliot Ohlstein, Raymond E. Stevens, Jr., H. Jeffrey Wilkins
  • Pharmaceutical compositions and the treatment of overactive bladder
    Patent number: 9907767
    Abstract: The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: March 6, 2018
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum
  • Pharmaceutical Combination
    Patent number: 9522129
    Abstract: Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: December 20, 2016
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum